Our Technology
is an easy to use transcatheter pulmonary valve for young children
Our Solution
We provide the only transcatheter pulmonary valve for children as young as 2 years old.
Patented biocompatible polymer tri-leaflet valve within a polymer-covered durable metal stent
Small incision, minimally invasive, non-surgical procedure
Designed to eliminate endocarditis complications caused by animal tissue valves
No immune system sensitization triggered by donor valves
Current Treatments
Allograft Donor Pulmonary Valves
All ages – from birth
- Requires open heart surgery
- Immune system sensitization
- High risk of complications
- Long hospital stays
- Poor durability
- Limited availability
Animal-Sourced Pulmonary Valves
Only available for teens and adults
- Suitable for open heart surgery and minimally invasive procedures
- Endocarditis, stent fractures, and valve degeneration are common
- Expensive and difficult to manufacture
Platform Technology
- Our stented polymer valve technology is readily scalable to larger sizes suitable for teens and adults that doubles the market opportunity to $180M in the US alone.
- PolyVascular’s polymer valve technology can be expanded to pursue the aortic, mitral, and tricuspid valve markets at >$11B globally.
Heart Valves
- Repeatable, scalable, reliable manufacturing process with established quality and inspection controls
- ISO 13485 compliant Quality Management System
- ISO class 7 clean room manufacturing space
- Fully equipped R&D lab including durability testing capital equipment
Our Accelerated Path to Market
Healing our children
